Navigation Links
Survival rates improve with better treatment options for medulloblastoma

Study led by St. Jude finds that by tailoring the intensity of radiation to individual patients and cutting short the length of intensive chemotherapy improves outcome for those// suffering medulloblastoma.

A team of investigators led by St. Jude Children’s Research Hospital has announced that improved treatment measures for childhood brain cancer medulloblastoma have markedly enhanced the rate of survival of children with this disease.

The treatment increased the overall five-year survival for 86 children with average-risk medulloblastoma from the current rate of 70 percent to 85 percent; and raised the rate of survival among the 48 high-risk patients from 55 percent to 70 percent. Patients are considered to be at average risk of treatment failure if their cancer has not spread following initial surgery to remove the tumor, or if the remaining tumor is very small. Patients are considered at high risk of failure if their tumor has spread following surgery or if the remaining tumors are larger than those of low-risk patients.

A report on these results appears in the September 7 issue of Lancet Oncology.The investigators were able to achieve the improved survival rates while reducing the amount of radiation and length of chemotherapy following surgery in average-risk patients from levels used in standard treatments, according to Amar Gajjar, M.D., co-chair of the St. Jude Department of Oncology and director of its Neuro-Oncology Division. The chemotherapy for average-risk patients was completed in 16 weeks, versus the standard treatment, which lasts 48 weeks. The new treatment not only reduced radiation to the brain and spinal cord, but also reduced the level of two chemotherapy drugs by 75 percent and 50 percent, respectively. This reduction in radiation and chemotherapy holds promise for lessening the long-term, troublesome side effects on intellectual development of young patients treated for this cancer, Gajjar said. In add ition to improving overall five-year survival of average-risk patients to 85 percent, this group had an 83 percent rate of event-free survival and a rate of five-year, event-free survival of 70 percent for high-risk patients. Event-free survival means that a child did not have medical complications or relapse that required further treatment.

Moreover, the improved treatment achieved a survival rate of 66 percent as compared to 30-40 percent among children whose cancer had spread.

The results of the current clinical trial, SJMB96, are especially significant because they represent a dramatic change from the 45 percent survival rate achieved two decades ago using just surgery and irradiation, according to Gajjar. The subsequent addition of chemotherapy before or after radiotherapy improved that survival rate to 65 percent for children aged 3 years or older who had medulloblastoma.

"We attribute our very promising results to the early use of high-dose radiotherapy after surgery--rather than waiting until after chemotherapy--in combination with short-term, intense chemotherapy," Gajjar said. "Shorter-term, intense chemotherapy is an especially important component of treatment that contributes to the improved survival of high-risk patients."

The researchers also showed that genetic differences exist in medulloblastoma tissues among children. These differences could be used to differentiate between children whose tumors are very aggressive and require novel experimental treatment and those children whose tumors are less aggressive and who could benefit from further reduction in treatment.

"These additional studies suggest that we can further reduce the long-term effects of treatment among some children by further reducing the treatment intensity," Gajjar said. The researchers previously reported that medulloblastoma consists of several distinct subgroups of this cancer that can be identified according to specific genetic abnormalities.

Source-Eurekalert
'"/>




Related medicine news :

1. Long-Term Survival can be Predicted by a Simple Lung Test
2. Hepatitis G May Boost HIV Survival
3. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
4. Longer Lung Cancer Survival
5. ICU Survival can be improved by Antibiotic use
6. Vasopressin Found To Boost Survival In Sudden Cardiac arrest
7. Improving Survival Rate Of Lung Cancer Patients
8. Combination Therapy Effective In Improving Lung Cancer Survival
9. Symptoms Found To Be A Good Predictor Of Cancer Survival
10. Survival Of Colon Cancer Patients
11. Public Defibrillators Found To Improve Survival Rate
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology: